427 related articles for article (PubMed ID: 32243226)
1. Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.
Tung NM; Boughey JC; Pierce LJ; Robson ME; Bedrosian I; Dietz JR; Dragun A; Gelpi JB; Hofstatter EW; Isaacs CJ; Jatoi I; Kennedy E; Litton JK; Mayr NA; Qamar RD; Trombetta MG; Harvey BE; Somerfield MR; Zakalik D
J Clin Oncol; 2020 Jun; 38(18):2080-2106. PubMed ID: 32243226
[TBL] [Abstract][Full Text] [Related]
2. ASTRO Radiation Therapy Summary of the ASCO-ASTRO-SSO Guideline on Management of Hereditary Breast Cancer.
Trombetta MG; Dragun A; Mayr NA; Pierce LJ
Pract Radiat Oncol; 2020; 10(4):235-242. PubMed ID: 32471709
[TBL] [Abstract][Full Text] [Related]
3. Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline.
Bedrosian I; Somerfield MR; Achatz MI; Boughey JC; Curigliano G; Friedman S; Kohlmann WK; Kurian AW; Laronga C; Lynce F; Norquist BS; Plichta JK; Rodriguez P; Shah PD; Tischkowitz M; Wood M; Yadav S; Yao K; Robson ME
J Clin Oncol; 2024 Feb; 42(5):584-604. PubMed ID: 38175972
[TBL] [Abstract][Full Text] [Related]
4. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
[TBL] [Abstract][Full Text] [Related]
5. Local treatment in patients with hereditary breast cancer: decision-making process in low-, moderate-, high-penetrance pathogenic germline mutation carriers.
Sibilio A; Curcio A; Toesca A; Rossi EMC; Corso G
Curr Opin Oncol; 2022 Nov; 34(6):614-622. PubMed ID: 36170166
[TBL] [Abstract][Full Text] [Related]
6. SEOM clinical guidelines in Hereditary Breast and ovarian cancer.
Llort G; Chirivella I; Morales R; Serrano R; Sanchez AB; Teulé A; Lastra E; Brunet J; Balmaña J; Graña B;
Clin Transl Oncol; 2015 Dec; 17(12):956-61. PubMed ID: 26669313
[TBL] [Abstract][Full Text] [Related]
7. PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology.
Miglietta F; Cinquini M; Dieci MV; Cortesi L; Criscitiello C; Montemurro F; Del Mastro L; Zambelli A; Biganzoli L; Levaggi A; Delle Piane C; Marchiò C; Calabrese M; Fortunato L; Franco P; Meduri B; Fittipaldo VA; Gori S
Breast; 2022 Dec; 66():293-304. PubMed ID: 36379199
[TBL] [Abstract][Full Text] [Related]
8. Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update.
Recht A; Comen EA; Fine RE; Fleming GF; Hardenbergh PH; Ho AY; Hudis CA; Hwang ES; Kirshner JJ; Morrow M; Salerno KE; Sledge GW; Solin LJ; Spears PA; Whelan TJ; Somerfield MR; Edge SB
J Clin Oncol; 2016 Dec; 34(36):4431-4442. PubMed ID: 27646947
[TBL] [Abstract][Full Text] [Related]
9. Is breast-conserving therapy adequate in BRCA 1/2 mutation carriers? The radiation oncologist's point of view.
Vallard A; Magné N; Guy JB; Espenel S; Rancoule C; Diao P; Deutsch E; Rivera S; Chargari C
Br J Radiol; 2019 May; 92(1097):20170657. PubMed ID: 30810334
[TBL] [Abstract][Full Text] [Related]
10. Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update.
Recht A; Comen EA; Fine RE; Fleming GF; Hardenbergh PH; Ho AY; Hudis CA; Hwang ES; Kirshner JJ; Morrow M; Salerno KE; Sledge GW; Solin LJ; Spears PA; Whelan TJ; Somerfield MR; Edge SB
Pract Radiat Oncol; 2016; 6(6):e219-e234. PubMed ID: 27659727
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer treatment in mutation carriers: surgical treatment.
Biglia N; D'Alonzo M; Sgro LG; Tomasi Cont N; Bounous V; Robba E
Minerva Ginecol; 2016 Oct; 68(5):548-56. PubMed ID: 26822896
[TBL] [Abstract][Full Text] [Related]
12. Locoregional Treatments and Ipsilateral Breast Cancer Recurrence Rates in BRCA1/2 Mutation Carriers.
Bernstein-Molho R; Laitman Y; Galper S; Jacobson G; Boursi B; Gal-Yam EN; Kaufman B; Friedman E; Kaidar-Person O
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1332-1340. PubMed ID: 33259931
[TBL] [Abstract][Full Text] [Related]
13. Hereditary breast cancer: translation into clinical practice of recent American Society of Clinical Oncology, American Society of Radiation Oncology, and Society of Surgical Oncology recommendations.
Corso G; Magnoni F
Eur J Cancer Prev; 2021 Jul; 30(4):311-314. PubMed ID: 32898012
[TBL] [Abstract][Full Text] [Related]
14. BRCA mutation testing in determining breast cancer therapy.
Smith KL; Isaacs C
Cancer J; 2011; 17(6):492-9. PubMed ID: 22157293
[TBL] [Abstract][Full Text] [Related]
15. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.
Kirova YM; Stoppa-Lyonnet D; Savignoni A; Sigal-Zafrani B; Fabre N; Fourquet A;
Eur J Cancer; 2005 Oct; 41(15):2304-11. PubMed ID: 16140006
[TBL] [Abstract][Full Text] [Related]
16. Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis.
Valachis A; Nearchou AD; Lind P
Breast Cancer Res Treat; 2014 Apr; 144(3):443-55. PubMed ID: 24567198
[TBL] [Abstract][Full Text] [Related]
17. Combined breast conservation therapy versus mastectomy for BRCA mutation carriers - A systematic review and meta-analysis.
Davey MG; Davey CM; Ryan ÉJ; Lowery AJ; Kerin MJ
Breast; 2021 Apr; 56():26-34. PubMed ID: 33582622
[TBL] [Abstract][Full Text] [Related]
18. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy.
Pierce LJ; Phillips KA; Griffith KA; Buys S; Gaffney DK; Moran MS; Haffty BG; Ben-David M; Kaufman B; Garber JE; Merajver SD; Balmaña J; Meirovitz A; Domchek SM
Breast Cancer Res Treat; 2010 Jun; 121(2):389-98. PubMed ID: 20411323
[TBL] [Abstract][Full Text] [Related]
19. Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series.
Robson M; Svahn T; McCormick B; Borgen P; Hudis CA; Norton L; Offit K
Cancer; 2005 Jan; 103(1):44-51. PubMed ID: 15558796
[TBL] [Abstract][Full Text] [Related]
20. Contribution of BRCA1 and BRCA2 germ-line mutations to the incidence of breast cancer in young women: results from a prospective population-based study in France.
Bonadona V; Sinilnikova OM; Chopin S; Antoniou AC; Mignotte H; Mathevet P; Brémond A; Martin A; Bobin JY; Romestaing P; Raudrant D; Rudigoz RC; Léoné M; Chauvin F; Easton DF; Lenoir GM; Lasset C
Genes Chromosomes Cancer; 2005 Aug; 43(4):404-13. PubMed ID: 15887246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
